Wearable health tech startup Ultrahuman has raised Rs 583 crore in a funding round led by Qualcomm Ventures to support its product expansion. While the company reported a revenue of Rs 651 crore for FY26, it also transitioned to a net loss of Rs 176 crore. Investors will likely monitor the firm's ability to balance rapid growth in competitive global markets like the US against the need for a sustainable profit margin.
Ultrahuman, an Indian health technology company known for its smart wearable devices, has secured Rs 583 crore in a new funding round. The investment was led by Qualcomm Ventures, with significant participation from Alpha Wave, Labcorp, and Blume Ventures. Zomato founder Deepinder Goyal also participated in the round. This capital infusion is intended to provide the company with the resources needed to scale its operations and invest further in product development.
Financial Context and Shift to Losses
The funding comes at a pivotal time for the company as it navigates a changing financial landscape. According to the company's fiscal data for FY26, Ultrahuman reported a revenue of Rs 651 crore, which marks a 15% increase compared to the previous year. However, the company also reported a net loss of Rs 176 crore, a significant change from the Rs 73 crore profit it posted in the previous fiscal year. This shift reflects higher spending on operations and development as the company attempts to capture more market share in the global wearable health sector.
US Market Strategy and Product Focus
The additional funding will play a key role in the company's efforts to strengthen its presence in the US market. The business experienced a setback in 2025 following a patent ruling that resulted in the withdrawal of its Ring Air product from that market. In response, Ultrahuman launched its redesigned Ring Pro in April to regain its footing and compete with established players in the fitness tracker category.
The company is now focused on optimizing its distribution and ensuring its latest wearable technology gains traction among consumers. For observers and stakeholders, the core challenge remains how the company manages the cost of scaling its business while facing intense competition from both global electronics giants and smaller niche health-tech startups.
Looking ahead, the main monitorables for the company will be its ability to improve operational efficiency and move back toward profitability. Investors will be watching for updates on how effectively the company can use this capital to increase its sales volume without continuing to widen its bottom-line losses. The sustainability of its business model in the face of ongoing competition and the regulatory environment in international markets will be key areas to track.